Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
Schizophr Res
; 239: 83-91, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-34847501
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Schizophrenia
/
Antipsychotic Agents
/
Risperidone
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
Schizophr Res
Journal subject:
PSIQUIATRIA
Year:
2022
Document type:
Article
Affiliation country:
Ukraine
Country of publication:
Netherlands